Alkem Laboratories Ltd
BSE:539523
Alkem Laboratories Ltd
BSE:539523
Price:
5 435
INR
2.58%
Market Closed
Market Cap:
₹649.8B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Alkem Laboratories Ltd
BSE:539523
|
IN |
|
Shun Tak Holdings Ltd
HKEX:242
|
HK |
|
Voyageurs du Monde SA
PAR:ALVDM
|
FR |
|
Power & Digital Infrastructure Acquisition II Corp
NASDAQ:AIRJ
|
US |
|
India Cements Ltd
NSE:INDIACEM
|
IN |
|
T
|
Thorne Healthtech Inc
F:F7G
|
US |
|
F
|
Friend Co Ltd
SSE:605050
|
CN |
|
Aura Biosciences Inc
NASDAQ:AURA
|
US |
|
V
|
Viva China Holdings Ltd
HKEX:8032
|
HK |
|
C
|
Cofle SpA
MIL:CFL
|
IT |
|
Threat Protect Australia Ltd
ASX:TPS
|
AU |
|
Akshar Spintex Ltd
NSE:AKSHAR
|
IN |
|
C
|
CTT Systems AB
LSE:0GUO
|
SE |
|
X
|
Xin Yuan Enterprises Group Ltd
HKEX:1748
|
CN |
|
Wingtech Technology Co Ltd
SSE:600745
|
CN |
Multiples-Based Value
The Multiples-Based Value of one
ALKEM
stock under the Base Case scenario is
hidden
INR.
Compared to the current market price of 5 435 INR,
Alkem Laboratories Ltd
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ALKEM Multiples-Based Value
LOCKED
Multiples Across Competitors
ALKEM Competitors Multiples
Alkem Laboratories Ltd Competitors
Alkem Laboratories Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
|
Alkem Laboratories Ltd
BSE:539523
|
649.9B INR | 4.6 | 27.4 | 21.1 | 24.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
865.7B USD | 13 | 41.1 | 27.7 | 29.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
576.1B USD | 6.1 | 21.5 | 14.9 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.4 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
295.4B USD | 4.5 | 16.1 | 10 | 12.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
218.1B GBP | 4.9 | 28.1 | 15.6 | 22 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.5B CHF | 5.2 | 21.1 | 13.1 | 16.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.5 | 10.5 | 7.8 | 9.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.1B USD | 2.5 | 20.2 | 7.7 | 10.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.6B USD | 2.5 | 17 | 7.2 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
